Skip to main content
. Author manuscript; available in PMC: 2011 Feb 9.
Published in final edited form as: J Allergy Clin Immunol. 2008 May;121(5):1175–1180. doi: 10.1016/j.jaci.2008.02.015

Table 2.

Varimax rotated factor pattern: randomization window (all subjects) n = 990

Factor
Lung Function Ratio/BD response Inflammatory/Atopy Symptoms Exacerbations
Pre-BD FEV1 0.979 0.161 0.024 −0.044 −0.056
Pre-BD FVC 0.975 −0.188 0.067 −0.005 −0.054
Pre-BD Peak Flow 0.750 0.120 0.123 −0.057 −0.030
Pre-BD FEV1/FVC ratio −0.085 0.942 −0.133 −0.106 0.012
FEV1 BD Responsiveness −0.178 0.644 0.240 0.157 0.023
Serum IgE level (ng/ml)* 0.100 −0.078 0.692 0.049 −0.037
No. of positive core skin tests 0.132 −0.017 0.583 0.109 −0.002
Total Eosinophil Count (mm3)* 0.007 −0.122 0.520 0.003 0.027
FEV1 PC20 methacholine, mg/ml* 0.109 0.292 0.428 −0.193 −0.066
Mean Symptom Score 0.055 −0.082 0.093 0.708 0.179
No. of days with albuterol puffs −0.050 −0.077 0.078 0.502 0.247
No. of episode-free days 0.081 0.096 −0.066 0.661 0.110
No. of doctor contacts −0.014 0.013 0.020 0.085 0.571
No. of school absences −0.037 0.021 −0.072 −0.025 0.541
No. of nights awakened −0.034 −0.067 0.095 0.218 0.359
No. of days with any prednisone use** NA NA NA NA NA
% Variance Explained 17.1% 10.1% 9.3% 8.9% 5.8%
*

Data was logarithimically transformed for factor analysis

**

Participants were taken off of Prednisone during the 28 day screening period but could use it afterwards

Common variance explained by all 5 factors: 58.9%